Insulet Wins $452M in Trade Secret Lawsuit Against EOFlow Over Insulin Pump

In a decisive legal victory, Insulet has been awarded $452 million in a trade secret lawsuit against South Korean firm EOFlow, concerning their insulin pump technology. The federal jury's ruling includes $170 million in compensatory damages and $282 million in punitive damages. The case centered around EOFlow's alleged misappropriation of trade secrets related to Insulet's wearable Omnipod insulin pumps, with the accusation that EOFlow employed former Insulet executives to facilitate the use of these secrets in their product design[1][2]. Despite EOFlow's advancements and regulatory success in markets outside of the U.S., the lawsuit impacted a major acquisition deal, leading to Medtronic canceling its planned purchase of EOFlow due to breaches of the agreement[1].